SCHEMBL6902380

SCHEMBL6902380

Cc1ccc(C(=O)CC(O)C(F)(F)F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.48
KMT2A Q03164 4/20 0.47
ALDH1A1 P00352 4/20 0.47
MAPT P10636 3/20 0.47
LMNA P02545 2/20 0.47
RAB9A P51151 4/20 0.46
NPC1 O15118 3/20 0.46
MEN1 O00255 2/20 0.46
ATM Q13315 1/20 0.46
POLB P06746 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
CA2 P00918 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
HPGD P15428 1/20 0.40
CETP P11597 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6902376 1.00 GSK3B (0.48) GSK3BKMT2AALDH1A1MAPTLMNA
SCHEMBL19775232 0.82 CA12 (0.51) KMT2AALDH1A1MAPTLMNARAB9A
SCHEMBL6904340 0.82 GSK3B (0.50) GSK3BKMT2AALDH1A1MAPTLMNA
SCHEMBL6900441 0.82 GSK3B (0.50) GSK3BKMT2AALDH1A1MAPTLMNA
SCHEMBL6900741 0.81 TSHR (0.55) GSK3BKMT2AALDH1A1MAPTLMNA
SCHEMBL6897949 0.81 TSHR (0.55) GSK3BKMT2AALDH1A1MAPTLMNA
SCHEMBL6897943 0.81 TSHR (0.55) GSK3BKMT2AALDH1A1MAPTLMNA
SCHEMBL6900403 0.81 HDAC3 (0.53) GSK3BALDH1A1MAPTLMNARAB9A
SCHEMBL6900410 0.81 HDAC3 (0.53) GSK3BALDH1A1MAPTLMNARAB9A
Acetic Acid SCHEMBL10333511 0.81 TSHR (0.50) GSK3BKMT2AALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7759497-B2 Synthesis of diaryl pyrazoles PFIZER INC. (US) 2010-07-20 US disclosed
US-20070004924-A1 such as (4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazole-1-yl]benzenesulfonamide), celecoxib, via reacting 1,3-diketone and 4-sulfamidophenyl hydrazine halide salt in solvent system containing isopropanol PHARMACIA CORPORATION 2007-01-04 US disclosed
US-6833468-B2 Reacting an optically active imine with a compound that is a hemiacetal of a perfluoroalkylaldehyde or a hydrate of a perfluoroalkylaldehyde to obtain a condensate, hydrolyzing CENTRAL GLASS COMPANY, LIMITED (JP) 2004-12-21 US disclosed
US-6642409-B2 Reacting an imine with a hemiacetal; hydrolysis under acid conditions CENTRAL GLASS COMPANY, LIMITED (JP) 2003-11-04 US disclosed
US-6639100-B2 Baeyer-Villiger oxidation of an optically active 4,4,4-tri-fluoro-3-hydroxy-1-aryl-1-butanone; purification by precipitation and removing racemic crystals; agriculture; drugs; ferroelectric liquid crystals; chemical intermediates CENTRAL GLASS COMPANY, LIMITED (JP) 2003-10-28 US disclosed
US-20030100767-A1 Reacting an optically active imine with a compound that is a hemiacetal of a perfluoroalkylaldehyde or a hydrate of a perfluoroalkylaldehyde to obtain a condensate, hydrolyzing CENTRAL GLASS COMPANY, LIMITED 2003-05-29 US disclosed
US-20030088095-A1 Reacting an optically active imine with a hemiacetal of a perfluoroalkylaldehyde or a hydrate; hydrolyzing the condensate under an acid condition. CENTRAL GLASS COMPANY, LIMITED 2003-05-08 US disclosed
US-20020016511-A1 Reacting an imine with a hemiacetal; hydrolysis under acid conditions CENTRAL GLASS COMPANY, LIMITED (JP) 2002-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100767-A1 Reacting an optically active imine with a compound that is a hemiacetal of a perfluoroalkylaldehyde or a hydrate of a perfluoroalkylaldehyde to obtain a condensate, hydrolyzing ADH1C, ADH1A, HPD GSK3B 1305/4885KMT2A 4162/4885ALDH1A1 31/4885
US-20070004924-A1 such as (4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazole-1-yl]benzenesulfonamide), celecoxib, via reacting 1,3-diketone and 4-sulfamidophenyl hydrazine halide salt in solvent system containing isopropanol KHK, GCK, SYMPK GSK3B 3815/4885KMT2A 1995/4885ALDH1A1 1197/4885
US-20030088095-A1 Reacting an optically active imine with a hemiacetal of a perfluoroalkylaldehyde or a hydrate; hydrolyzing the condensate under an acid condition. ADH1C, ADH1A, HPD GSK3B 1044/4885KMT2A 4098/4885ALDH1A1 25/4885
US-20020016511-A1 Reacting an imine with a hemiacetal; hydrolysis under acid conditions ADH1C, ADH1A, HPD GSK3B 888/4885KMT2A 3880/4885ALDH1A1 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.